==> picture [157 x 72] intentionally omitted <==

Corum Group Limited ABN 25 000 091 305 Level 3, 120 Sussex Street, Sydney NSW 2000 www.corumgroup.com.au

Market Release

24 February 2021

Corum building positive momentum

Corum Group Limited (ASX:COO) (Corum) is pleased to announce its interim results for FY21.

Group revenue $6.64m UP 33% on pcp
Underlying EBITDA $2.2m UP 2,501% on pcp
Cash on hand $7.6m

Key operational highlights

Completion of the PharmX acquisition. Corum acquired the remaining 57% of equity in PharmX for $7.9m
Successful capital raise. Corum undertook a 1 for 3 Non-renounceable Rights issue to raise $5.6m before costs at 4.2cps to part fund the PharmX acquisition
Strategic placement to Arrotex pharmaceuticals. Corum secured Arrotex pharmaceuticals, Australia’s largest generic and private label OTC company as a strategic shareholder. This placement raised a further $3.3m at 5.5cps and Dennis Bastas, Executive Chairman of Arrotex joined the Corum Board
Revenue growth of $6.64m was an increase of 33% on pcp aided by the PharmX acquisition. Expenses continue to be closely controlled
Underlying EBITDA of $2.2m was an increase of 2,501% on pcp.
Corum ended the half with a strong cash balance and is well positioned to take advantage of strategic opportunities as they occur
Cash from operating activities was positive $559k vs $1,315 negative in pcp

Commenting on the results, Corum Managing Director, Julian Sallabank said: “I am pleased with the continued progress that we have achieved in the half year. We will continue to focus on profitable growth of our healthcare business and look to augment that growth through disciplined healthtech acquisitions”.

- ENDS -

This announcement has been authorised for lodgment by Julian Sallabank, Managing Director

For further information contact:

Julian Sallabank, Managing Director

Investor email: [email protected]

==> picture [595 x 31] intentionally omitted <==

----- Start of picture text -----

Corum Group | Corum Health | Corum eCommerce | PharmX corumgroup.com.au
----- End of picture text -----

==> picture [157 x 72] intentionally omitted <==

Corum Group Limited ABN 25 000 091 305 Level 3, 120 Sussex Street, Sydney NSW 2000 www.corumgroup.com.au

About Corum Group

Corum Group Limited [ASX:COO] (Corum) is an Australian company limited by shares that owns businesses in technology and software development.

For more than 30 years Corum has been using its deep industry expertise and extensive relationships to develop PointOf-Sale, Dispensing and Management software for pharmacy head offices and retail stores and a range of eCommerce and ordering solutions throughout Australia.

Corum is determined to offer the best solutions to its customers through the products, services and processes of each of its businesses.

==> picture [595 x 31] intentionally omitted <==

----- Start of picture text -----

Corum Group | Corum Health | Corum eCommerce | PharmX corumgroup.com.au
----- End of picture text -----

==> picture [244 x 451] intentionally omitted <==

Corum Group Limited

H1 FY21 Results 24 February 2021

Important Notice & Disclaimer

This presentation has been prepared by Corum Group Limited (COO or the Company or Corum). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in COO, or as an inducement to purchase any shares in COO. No agreement to subscribe for securities in COO will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licensed to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements do not guarantee of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making.

Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates an each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

Although the Company believes that the expectations reflected in the forwardlooking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any

==> picture [58 x 25] intentionally omitted <==

H1 FY21 Key Highlights

==> picture [624 x 52] intentionally omitted <==

----- Start of picture text -----

Financials
----- End of picture text -----

Revenue $6,642k , an increase of 33% on pcp
Heath Services $5,774k, up 43% on pcp
eCommerce $780k, down 18% on pcp
Underlying EBITDA $2.2m[(1)] compared to $0.1m in pcp, up 2,501%
Underlying NPAT of $1.5m[(2)] compared to a loss of ($0.5)m in pcp
Underlying EPS of 0.31 cents per share[(2)] compared to a loss of 0.11 cents per share in pcp
Operating cashflow was $559k in the half
Cash on hand at 31 December 2020 of $7.6m

==> picture [58 x 25] intentionally omitted <==

(1) Excluding PharmX + BAMM legal costs / restructuring / redundancy $0.8m

(2) Excluding PharmX + BAMM legal costs / restructuring / redundancy $0.8m, BAMM Settlement $1.5m, fair value adjustments $1.7m

H1 FY21 Ke Hi hli hts y g g

==> picture [624 x 25] intentionally omitted <==

----- Start of picture text -----

PharmX Acquisition
----- End of picture text -----

Acquisition of the 57% equity in PharmX that Corum did not already own
The Corum Board expect the acquisition to be earnings per share accretive in its first year

==> picture [624 x 25] intentionally omitted <==

----- Start of picture text -----

Capital Raising
----- End of picture text -----

Corum undertook a 1 for 3 Non-Renounceable Rights issue (“Offer”) to raise $5.6 million before costs at 4.2 cps as part funding for the acquisition
The Corum Board and their related entities participated fully for their respective entitlements & collectively hold 28% of the listed equity
Strategic placement to Arrotex Pharmaceuticals raising a further $3.3m at 5.5 cps

==> picture [624 x 25] intentionally omitted <==

----- Start of picture text -----

Corporate
----- End of picture text -----

Appointment of Julian Sallabank as CEO and Managing Director effective 1 September 2020
Board Renewal complete with the appointment of Jayne Shaw (Oct 20) and Dennis Bastas (Dec 20) further enhancing the capabilities & reach of the Corum Board
Secured Arrotex Pharmaceuticals as a strategic shareholder . Arrotex is Australia’s largest generic and private label OTC company servicing 3,400 pharmacies
Concluded BAMM agreement – Research & Development now in house providing greater control over product development

Australian Pharmacy Market

Corum operates primarily within the Australian pharmacy sector as a software vendor & technology provider

Australian Pharmacies[2]

Group Market Segment[1]

==> picture [196 x 180] intentionally omitted <==

----- Start of picture text -----

13% 15%
34%
38%
----- End of picture text -----

Buying Groups Banners Groups Brands

==> picture [180 x 100] intentionally omitted <==

----- Start of picture text -----

PBS Registered
3%
95% Private Hospitals
2%
Public Hospitals
----- End of picture text -----

Australian Pharmacy Market Share[2]

==> picture [214 x 112] intentionally omitted <==

----- Start of picture text -----

38% My Chemist Retail Group
Sigma Healthcare Ltd
10%
$20bn EBOS Group Ltd
Australian Pharmaceutical
12%
23% Industries
Other
18%
----- End of picture text -----

==> picture [58 x 25] intentionally omitted <==

1Corum Estimates 2IBIS World April 2020

Corum Group

Corum Group is a key enabler of Australian community pharmacy through its diversified pharmacy digital infrastructure

==> picture [248 x 29] intentionally omitted <==

----- Start of picture text -----

Revenue Source
----- End of picture text -----

Dispense, Point of Sale and Head Office software (subscriptions under licences) FY20 Pro-forma
• Typically payable quarterly in advance 18% 13%
• Pre-eminent electronic ordering gateway
• Platform access and usage charges payable monthly for agreed term 82% 87%
• Outsourced payment processing platform eCommerce PharmacyHealth Services
Outsourced payment processing platform
• Primarily transaction value-based charges payable quarterly in advance, monthly or per transaction

==> picture [58 x 25] intentionally omitted <==

Our Pharmacy Software Solutions

Corum Health is a key enabler of Australian community pharmacy through it’s Dispense, Point of Sale and Head Office pharmacy digital infrastructure

Solutions

Medication dispense systems are highly regulated
ePrescribing ready in a post COVID environment
• Corum Clear Dispense ( CCD ) in market and expanding rapidly
Manage front of house cash collection
Also serve as stock ordering and control system Retail
• Corum Clear Retail ( CCR ) focused on enhancing existing functionality and performance
Pharmacy group management solutions
RPM is the market leading head office system
• Corum Clear Enterprise ( CCE ) scheduled for pilot 4Q FY21

==> picture [58 x 25] intentionally omitted <==

PharmX Overview

PharmX is the pre-eminent electronic ordering gateway for Australian pharmacy with a long track record of delivering the stability and reliability required by the high order volumes of pharmacies

Key Pharmacy Benefits Key Supplier Benefits
• Access all wholesalers • Single access point to Australian pharmacy
• Broad range of POS systems •
supported including all major Facilitates electronic ordering vendors without customised interfaces
• Connecting 5,500+ • Increases ordering efficiency Increases pharmacy supply chain saving valuable staff time pharmacies to their efficiency suppliers
• Broad range of direct suppliers connected and accessible Connected Wholesalers Selected Connected Suppliers

==> picture [55 x 28] intentionally omitted <==

==> picture [54 x 28] intentionally omitted <==

==> picture [55 x 28] intentionally omitted <==

==> picture [53 x 27] intentionally omitted <==

==> picture [52 x 27] intentionally omitted <==

==> picture [53 x 27] intentionally omitted <==

==> picture [58 x 25] intentionally omitted <==

PharmX Opportunities

There is a renewed strategic focus , the Corum Board believes the past 3 years of equity holder litigation have acted as a significant distraction to the strategic focus of PharmX

==> picture [298 x 26] intentionally omitted <==

----- Start of picture text -----

Capital Investment
----- End of picture text -----

Corum will provide PharmX with capital investment to achieve growth ambitions based on expected profitability and managed risk

==> picture [298 x 26] intentionally omitted <==

----- Start of picture text -----

Extend Supplier Depth
----- End of picture text -----

PharmX is focused on expanding the number of platform connected suppliers given the efficiency benefits for the pharmacy supply chain

==> picture [297 x 26] intentionally omitted <==

----- Start of picture text -----

Additional Services
----- End of picture text -----

PharmX management have identified a range of potential additional services to further improve pharmacy supply chain efficiency

==> picture [297 x 26] intentionally omitted <==

----- Start of picture text -----

Alternative Markets
----- End of picture text -----

Potential exists for the deployment of the PharmX technology platform across alternative market opportunities

==> picture [58 x 25] intentionally omitted <==

eCommerce

Corum eCommerce provides its clients a simple and efficient outsourced payment processing platform

==> picture [348 x 45] intentionally omitted <==

ReConnect oneCard

Secure payment solution primarily used by Real Estate agents without the need to maintain their own secure payment IT infrastructure

eCpay

Corporate grade payment solution offering customised features that is fast, reliable and secure and can be integrated to client requirements

Our eCommerce Solution

Secure PCI compliant payment gateway
Provides clients an efficient payment method for customers
Avoids the need for clients to maintain expensive payment systems
Full support desk service

Select Clients

==> picture [61 x 8] intentionally omitted <==

==> picture [57 x 27] intentionally omitted <==

==> picture [57 x 12] intentionally omitted <==

==> picture [57 x 18] intentionally omitted <==

==> picture [58 x 32] intentionally omitted <==

==> picture [50 x 22] intentionally omitted <==

==> picture [58 x 25] intentionally omitted <==

==> picture [262 x 454] intentionally omitted <==

Financials

H1 FY21 Financial Snapshot

Results1 H1 FY20 H1 FY21 ∆ PCP Revenue $5,011 $6,642 33% Health Services2 $4,056 $5,862 45% eCommerce $955 $780 -18% Expenses ($4,926) ($5,203) 6% EBITDA (reported) $85 $1,439 1,593% EBITDA (underlying)3 $85 $2,211 2,501%	Results1 H1 FY20 H1 FY21 ∆ PCP Revenue $5,011 $6,642 33% Health Services2 $4,056 $5,862 45% eCommerce $955 $780 -18% Expenses ($4,926) ($5,203) 6% EBITDA (reported) $85 $1,439 1,593% EBITDA (underlying)3 $85 $2,211 2,501%	Results1 H1 FY20 H1 FY21 ∆ PCP Revenue $5,011 $6,642 33% Health Services2 $4,056 $5,862 45% eCommerce $955 $780 -18% Expenses ($4,926) ($5,203) 6% EBITDA (reported) $85 $1,439 1,593% EBITDA (underlying)3 $85 $2,211 2,501%	Results1 H1 FY20 H1 FY21 ∆ PCP Revenue $5,011 $6,642 33% Health Services2 $4,056 $5,862 45% eCommerce $955 $780 -18% Expenses ($4,926) ($5,203) 6% EBITDA (reported) $85 $1,439 1,593% EBITDA (underlying)3 $85 $2,211 2,501%
Revenue Health Services2 eCommerce Expenses EBITDA (reported) EBITDA (underlying)3	$5,011 $4,056 $955 ($4,926) $85 $85	$6,642 $5,862 $780 ($5,203) $1,439 $2,211	33% 45% -18% 6% 1,593% 2,501%

Increases in Health Services revenue in line with expectations mainly due to PharmX contribution
Continued focus on organisational efficiencies and revenue generation delivered significant uplift in EBITDA
First revenue uplift since FY16 and EBITDA Margin of 37%

Sales Revenue ($000’s)

==> picture [301 x 97] intentionally omitted <==

----- Start of picture text -----

H2
$7,352 H2
$6,473 H2
$5,348 $4,813H2 H2
$4,605
H1
$8,201 $7,034H1 $5,828H1 $5,321H1 $4,511H1 $5,977H1
FY16 FY17 FY18 FY19 FY20 FY21
----- End of picture text -----

==> picture [309 x 173] intentionally omitted <==

----- Start of picture text -----

Underlying EBITDA ($000’s) & EBITDA Margin (%) [4]
$4,000 37.0% 40.0%
$3,000 30.0%
$2,000 20.0%
$2,211
$1,000 10.0%
- 0.0%
FY16 FY17 FY18 FY19 FY20 H1 FY21
Underlying EBITDA EBITDA Margin
----- End of picture text -----

1Refer to Page 22 in the appendix for detailed financial statements

==> picture [58 x 25] intentionally omitted <==

2 Includes unallocated segment revenue of $88k in H1 FY21 and $24k in H1 FY20
3Adjusted to exclude one-off costs – see Page 13 Profit & Loss for detail on underlying calculations 4FY16 to FY20 is reported EBITDA, H1 FY21 is adjusted underlying EBITDA

Underlying Result Reconciliation

EBITDA	H1 FY21	NPAT	H1 FY21
		Underlying EBITDA	$2,211
Revenue	$6,642	Depreciation & Amortisation, interest and tax	($710)
Expenses	($5,203)	Underlying NPAT	$1,501
Reported EBITDA	$1,439	PharmX + BAMM legal costs / restructuring / redundancy	($772)
PharmX + BAMM legal costs / restructuring / redundancy	$772	BAMM settlement FV adjustment on PharmX investment	($1,468) $1,727
Underlying EBITDA	$2,211	Reported NPAT	$988

Underlying Results Reconciliation

==> picture [560 x 93] intentionally omitted <==

----- Start of picture text -----

$0.7m
$0.8m
$2.2m
$1.7m
$1.5m $1.5m
$1.0m
----- End of picture text -----

Underlying EBITDA

Depreciation & Underlying NPAT BAMM Settlement FV adjustment on PharmX + BAMM Reported NPAT Amortisation, PharmX investment legals / restructuring interest and tax / redundancy

==> picture [58 x 25] intentionally omitted <==

Positive Cashflow Momentum

Net cash from / (Used in) Operating Activities ($’000)[1]

==> picture [570 x 248] intentionally omitted <==

----- Start of picture text -----

•
Operating cashflow improvement a key
$559 focus for new Board
• Positive H1 run rate in FY21
$191
•
Cost optimisation a focus to minimise
COVID-19 impact
•
Cashflow data excludes any PharmX
contribution which was accrued during
FY20
($1,315)
H1 FY20 H2 FY20 H1 FY21
----- End of picture text -----

==> picture [58 x 25] intentionally omitted <==

1Adjusted to remove the impact of an R&D tax incentive credit received

Strategic Priorities

Improve sales performance in core pharmacy software
Continued focus on cost optimisation
Realise operating leverage in technology business
Corum Clear to be the lead solution suite
Streamline product range going forward
Focusing on return on development spend
Health software and related technologies
Leverage core pharmacy position and industry relationships
Disciplined approach to profitable growth

==> picture [58 x 25] intentionally omitted <==

FY21 Interim Summary

==> picture [59 x 59] intentionally omitted <==

==> picture [59 x 60] intentionally omitted <==

==> picture [60 x 60] intentionally omitted <==

Profitability restored & generating cash

Platform For Growth

Healthtech Focus

First revenue uplift since Over the past 12 months Provides investors exposure FY16 and EBITDA Margin Corum has put in place to a long established of 37% combined with strengthened healthcare, pharmacy technology Positive H1 run rate in technology and commercial business with a strategy to FY21 capabilities to target growth augment growth through disciplined healthtech acquisitions

==> picture [59 x 59] intentionally omitted <==

Refreshed Board & management with significant equity

Corum has strengthened its pharmacy sector relationships and access through Board renewal[1] and the acquisition of PharmX

==> picture [58 x 25] intentionally omitted <==

1Refer to Page 20-21 in the appendix for director profiles

==> picture [262 x 453] intentionally omitted <==

Questions

==> picture [262 x 453] intentionally omitted <==

Appendix

Corporate Overview

Corum Group Limited (ASX:COO)	Corum Group Limited (ASX:COO)
Share Price	9.0cps
Market Capitalisation	$55.49m
Enterprise Value (Cash 31/12/20)	$47.87m

==> picture [302 x 227] intentionally omitted <==

----- Start of picture text -----

Share Price Performance [1]
12c 8
8c
4
4c
0c 0
Feb-20 Apr-20 Jun-20 Aug-20 Oct-20 Dec-20 Feb-21
Volume Share Price
Volume (m)
----- End of picture text -----

Capital Structure	Capital Structure
Shares on Issue (m)	596.8
Options / Perf Rights (m)	5.6
Diluted Issued Capital (m)	602.4

Major Shareholders – 22 February 2020	Major Shareholders – 22 February 2020	Major Shareholders – 22 February 2020
	Shares (m)	%
Lujeta Pty Ltd	110.6	18.53
Arrotex Investments	60.0	10.05
National Nominees Limited	34.6	5.80
Lyell Pty Ltd	28.1	4.70
Mersault Pty Ltd	26.8	4.49
DG Manuel & AE Leary	26.7	4.47
Benki Pty Ltd	19.7	3.29
Ginga Pty Ltd	21.1	3.54
Milburn Pty Ltd	16.0	2.68

==> picture [58 x 25] intentionally omitted <==

1iress

Board & Management

==> picture [625 x 21] intentionally omitted <==

----- Start of picture text -----

Nick England - Chairman
----- End of picture text -----

==> picture [51 x 52] intentionally omitted <==

Nick has over 35 years of consulting and senior executive experience in Australia, the UK and Europe.

Nick held senior management roles with Alliance UniChem PLC (now AB Walgreens) which operates more than 18,000 pharmacies across multiple countries. As Group Director of Alliance UniChem, Nick was responsible for developing opportunities with key global network partners.

Nick’s experience includes roles with direct responsibility for managing strategy, sales and business performance.

==> picture [625 x 21] intentionally omitted <==

----- Start of picture text -----

Julian Sallabank - Managing Director
----- End of picture text -----

==> picture [44 x 44] intentionally omitted <==

Julian has vast experience in senior executive and board roles for both private and ASX listed companies operating in the medical technology and recruitment sectors.

Primary areas of expertise are strategic planning, commercialisation and organisational development of both domestic and international businesses.

Most recently Julian was Managing Director of an early stage medical innovation fund investing in and commercialising digital health, diagnostics, medtech and therapeutics; collaborating with the Murdoch Children’s Research Institute.

==> picture [625 x 24] intentionally omitted <==

----- Start of picture text -----

Jon Newbery - Non-Executive Director
----- End of picture text -----

==> picture [51 x 51] intentionally omitted <==

Jon brings to Corum over 30 years of senior executive and board roles for ASX listed companies in the technology, telecommunications, engineering and facilities management sectors.

Jon is currently Head of Corporate Finance and Projects for ASX listed Downer EDI with responsibility for strategic acquisitions and disposals for the group.

Previously Jon held roles as Chief Executive Officer of ASX listed Clarity OSS Limited and as Non-Executive Chairman of UK based platform developer IMX Software.

==> picture [58 x 25] intentionally omitted <==

Board & Management

==> picture [625 x 19] intentionally omitted <==

----- Start of picture text -----

Jayne Shaw - Non-Executive Director
----- End of picture text -----

==> picture [51 x 51] intentionally omitted <==

Ms Shaw has significant experience in healthcare management and an experienced clinical background in nursing. Ms Shaw has acted in senior management roles in two Australian private hospitals and established an Australian and international consulting business which was sold to Healthsouth, a large US Healthcare company.

After this, Jayne became the co-founder of Vision Group, a business that was successfully listed on the ASX.

Jayne has been a member of a number of private healthcare boards involved with specialist consolidation including cardiology, cancer care, orthopaedics, and women’s health and has continued to work with private equity firms on local and International Healthcare transactions.

Ms Shaw also holds positions on the boards of Mable Technologies, The Woolcock Research Institute, and The Citadel Group, and as Chairman of BCAL Diagnostics.

==> picture [625 x 20] intentionally omitted <==

----- Start of picture text -----

Dennis Bastas - Non-Executive Director
----- End of picture text -----

==> picture [51 x 52] intentionally omitted <==

Dennis has operated as an entrepreneur in Australia’s pharmaceutical sector since 2002 when he founded his first generic pharmaceutical company Genepharm. Over the past two decades he has gained extensive experience in the global pharmaceutical manufacturing industry and the Australian and Asian retail pharmacy market.

Dennis is currently the majority shareholder and Executive Chairman of two of Australia’s leading generic pharmaceutical companies, Arrotex Pharmaceuticals and Juno Pharmaceuticals.

Arrotex Pharmaceuticals is Australia’s largest generic pharmaceutical and private label OTC medicines company. Arrotex Pharmaceuticals was formed following the merger of Arrow Pharmaceuticals and Apotex Australia in July 2019 and is today Australia’s largest privately owned pharmaceutical company. Arrotex distributes medicines that account for over 30% of all PBS prescriptions dispensed in Australian pharmacies.

==> picture [58 x 25] intentionally omitted <==

Profit & Loss

H1 FY19	H2 FY19	H1 FY20	H2 FY20	H1 FY21 $6,642 $5,862 $780 ($1,040) ($3,384) ($53) ($60) ($385) ($386) ($92) - $197 ($5,203) $1,439 $2,211 ($781) $1,430 ($20) $91 $1,501 ($772) $1,727 ($1,468) $988	∆ PCP 33% 44.5% -18.3% 81.2% -12.1% -37.6% -74.9% 33.7% 306.3% 338.1% -12.4% 5.6% 1592.9% 2501.2% 103.9% 579.9% -16.7% 405.6% 593.8% 425.0%	∆ H2 FY20

$5,845	$5,385	$5,011	$5,632	$6,642	33%	18%
$4,698 $1,147 ($542) ($3,931) ($390) ($262) ($278) ($54) ($188) - $328	$4,315 $1,070 ($600) ($3,180) ($3) ($363) ($258) ($288) ($350) - $100	$4,056 $955 ($574) ($3,849) ($85) ($239) ($288) ($95) ($21) - $225	$4,763 $869 ($629) ($3,327) ($39) ($235) ($306) ($396) ($135) ($18) $363	$5,862 $780 ($1,040) ($3,384) ($53) ($60) ($385) ($386) ($92) - $197	44.5% -18.3% 81.2% -12.1% -37.6% -74.9% 33.7% 306.3% 338.1% -12.4%	23.1% -10.2% 65.3% 1.7% 35.9% -74.5% 25.8% -2.5% -31.9% -100.0% -45.7%
($5,317)	($4,942)	($4,926)	($4,722)	($5,203)	5.6%	10.2%

$528	$443	$85	$910	$1,439	1592.9%	58.1%

$528	$443	$85	$910	$2,211	2501.2%	143.0%
($209)	($201)	($383)	($418)	($781)	103.9%	86.8%
$319	$242	($298)	$492	$1,430	579.9%	190.7%
- ($161)	- ($61)	($24) $18	($26) ($300)	($20) $91	-16.7% 405.6%	-23.1% 130.3%
$158	$181	($304)	$166	$1,501	593.8%	804.2%
- ($2,450) -	- ($2,094) -	- - -	- $314 -	($772) $1,727 ($1,468)
($2,292)	($1,913)	($304)	$480	$988	425.0%	105.8%

==> picture [58 x 25] intentionally omitted <==

Balance Sheet

Balance Sheet (A$000's) Current assets Cash and cash equivalents Trade and other receivables Inventories Income tax receivable Other assets Total Non-current assets Investments Property, plant and equipment Right of use assets Intangibles Deferred tax assets Security deposits Total Total assets Current Liabilties Trade and other payables Provisions Lease Liabilty Deferred revenue Total Non-current liabilities Other payables Provisions Lease Liabilty Deferred Tax liabilty Total Total Liabilities Net assets	FY20		H1 FY21
	$2,323 $7,623 $3,826 $1,426 $64 $34 $1,700 $779 $1,928 $1,904 $9,841 $11,766 $2,686 - $525 $537 $702 $512 $4,674 $18,244 $551 $949 $199 $199 $9,337 $20,441 $19,178 $32,207 $3,628 $5,476 $1,202 $1,152 $422 $457 $226 $194 $5,478 $7,279 - $698 $192 $174 $311 $86 - $1,143 $503 $2,101 $5,981 $9,380 $13,197 $22,827
	$9,841		$11,766
	$2,686 $525 $702 $4,674 $551 $199		- $537 $512 $18,244 $949 $199
	$9,337		$20,441

	$19,178		$32,207
	$3,628 $1,202 $422 $226		$5,476 $1,152 $457 $194
	$5,478		$7,279
	- $192 $311 -		$698 $174 $86 $1,143
	$503		$2,101

	$5,981		$9,380

	$13,197		$22,827

==> picture [58 x 25] intentionally omitted <==

Share Registry

Top holders as of 22 February 2021

Rank	Name	Units	% Units
1	LUJETA PTY LTD	110,573,181	18.53
2	ARROTEX INVESTMENTS HOLDING 1 PTY LTD	60,000,000	10.05
3	NATIONAL NOMINEES LIMITED	34,583,841	5.80
4	MERSAULT PTY LTD	26,766,667	4.49
5	BENKI PTY LTD	19,655,748	3.29
6	MR DAVID GERALD MANUEL + MS ANNE ELIZABETH LEARY	18,666,667	3.13
7	LYELL PTY LTD	17,388,974	2.91
8	MILBURN PTY LTD	15,988,641	2.68
9	GINGA PTY LTD	14,414,488	2.42
10	MRS PENELOPE KING	13,333,334	2.23
11	LINK ENTERPRISES (INTERNATIONAL) PTY LTD	13,090,345	2.19
12	MR GRANT POVEY	12,000,000	2.01
12	SEVENIRON PTY LTD	12,000,000	2.01
14	LYELL PTY LTD	10,666,666	1.79
15	SANDHURST TRUSTEES LTD	9,761,905	1.64
16	CANCELER PTY LTD	9,600,000	1.61
17	MR DAVID GERALD MANUEL + MS ANNE ELIZABETH LEARY	8,000,000	1.34
17	MR TYSON WELLMAN	8,000,000	1.34
19	GABODI PTY LIMITED	7,197,334	1.21
20	MR JOHN LAGANA	6,800,586	1.14
Totals: Top	20 holders of FULLY PAID ORDINARY (Total)	428,488,377	71.80
Total Remaining Holders Balance		168,268,412	28.20

==> picture [58 x 25] intentionally omitted <==

==> picture [255 x 454] intentionally omitted <==

Corum Group Limited

Contact: [email protected]

AI assistant

PHARMX TECHNOLOGIES LIMITED — Interim / Quarterly Report 2021

65560_rns_2021-02-23_b1aa72a1-47cc-4a6a-98fb-3f7800873009.pdf